Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Hua Medicine Completes $117 Million Funding for Novel Diabetes Treatment

publication date: Mar 28, 2018

Shanghai's Hua Medicine closed a combined Series D & Series E financing of $117.4 million, which the company says will be enough to fund two clinical trials and commercial launch of its novel oral treatment for type 2 diabetes in China. The candidate, dorzagliatin (HMS5552), is a novel first-in-class, 4th-generation glucokinase activator (GKA). It works by improving the reaction of impaired blood glucose sensors, producing insulin in response to higher glucose levels. Hua expects China approval of dorzagliatin in 2020. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here